nuclear matrix protein 22

04/01/2000 - "The purpose of this study was to evaluate, from the perspective of the Quebec health system, the cost and cost-efficacy of using NMP22 compared with the currently recommended monitoring procedure following a transurethral resection of a bladder tumor (TURBT). "
12/01/2008 - "Combining NMP22 with malignant or suspicious cytological result improved sensitivity for the detection of bladder cancer but with a major decrease in specificity, suggesting a potential role in screening rather than diagnosis."
03/01/2006 - "The NMP22 BladderChek test is an in vitro qualitative test that is easily available and cheap; it can be performed by a urologist in the office and results can be interpreted within 30 min. The NMP22 test is superior to cytology for all grades and stages in the detection of recurrence in patients with a history of superficial bladder cancer. "
03/01/2011 - "The NMP22 test may be considered a new gold standard for the assessment of patients with known or suspected bladder cancer."
03/01/2011 - "This study aimed to compare the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of urine cytology, BladderChek® nuclear matrix protein-22 (NMP22) and UroVysion™ fluorescence in situ hybridization (FISH) tests in patients with newly diagnosed bladder cancer, those with recurrent bladder cancer, and those with bladder cancer but in remission during surveillance. "

09/01/1999 - "NMP22 and BTA stat test results represented significant improvement over urinary cytology for detection of transitional cell carcinoma. "
02/01/1998 - "NMP22 values represented significant improvement over urinary cytology for detection of transitional cell carcinoma. "
10/01/1996 - "Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). "
10/01/1996 - "Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. "
10/01/1996 - "Three groups of subjects participated in this trial of NMP22: 1-175 with transitional cell carcinoma, 2-117 with benign urinary tract conditions and 3-375 healthy volunteers. "

05/01/2012 - "For the primary diagnosis of bladder carcinoma, neither the UBC rapid nor the NMP22 BladderChek POC test systems are sensitive to the presence of blood in the urine, whereas BTA stat consistently yields false-positive results due to cross-reactivity to macrohaematuria and microhaematuria up to a density of 150 erythrocytes/μl, thus this system should not be employed for this examination."
09/01/2012 - "uRNA and Cxbladder showed improved sensitivity for the detection of urothelial carcinoma compared to the NMP22 assays. "
10/01/2013 - "The aim of this study is to evaluate the diagnostic values of the fluorescence in situ hybridization (FISH), NMP22 BladderChek, and liquid-based cytology (LBC) in the detection of bladder urothelial carcinoma (UC). "
02/01/2022 - "Retraction Notice to: Nuclear Matrix Protein 22 in Voided Urine Cytology Efficacy in Risk Stratification for Carcinoma of Bladder."
01/01/2022 - "Preoperative NMP22 and CSTB conveying is hardly interrelated to postoperative recurrence of bladder carcinoma and has certain appraisal worth for postoperative recurrence of bladder carcinoma, and the combined testing of the two has a taller appraisal worth. "

11/01/2014 - "It was associated with age greater than 65 (11.1% vs 4% of patients, p = 0.012), male gender (10.1% vs 2%, p = 0.003), white ethnicity (9.2% vs 3.1%, p = 0.016), gross hematuria (9.9% vs 2.5%, p = 0.005), positive NMP22 (37% vs 3.7%, p <0.001) and positive cytology (83.3% vs 3.9%, p <0.001). "
07/01/2010 - "Markers such as the Urovysion FISH assay and the NMP22 BladderChek test are approved for surveillance and detection in patients with hematuria. "
04/01/2008 - "Group 2:15 patients with history of hematuria underwent cystoscopy and NMP22 BladderChek. "
01/01/2006 - "On the other hand, the results obtained with BladderChek NMP22 need to be interpreted carefully because the test can yield a false-positive outcome in the presence of marked hematuria, pyuria or cytolysis of normal urotherium. "
11/01/2010 - "The recently initiated [Bladder Cancer Urine Marker Project (BLU-P) study www.blu-project.org] assesses the feasibility of a population-based screening for BC and at the same time evaluates a screening algorithm using next to hematuria testing, sensitive specific urine markers for BC (NMP22, FGFR3, MA analyses and MLPa) in an attempt to circumvent the high number of cystoscopies. "

08/01/2002 - "False-positive results on BTA Stat in 2 of 22 patients (9%), on NMP22 in 2 of 25 (8%), on 486p3/12 in 3 of 11 (27%) and on Lewis X in 4 of 43 (9.3%) were associated with tumor recurrence. "
12/01/2020 - "NMP22 was expressed immunohistochemically in 87/95(91.6%) of cases and was negative in 8/95(8.4%) of cancers. "
12/01/2020 - "Chi-square test and crosstabs were used to correlate grade and stage of urothelial tumors with gender and NMP22 expression. "
01/01/2018 - "In addition, TSGA10 expression was correlated with expression of NMP22 in both cancer patients and controls. "
06/01/2015 - "The NMP22 test could be useful for determining the frequency of cystoscopy and for early detection of high-grade tumors. "